M
Matthew J. Grainge
Researcher at University of Nottingham
Publications - 161
Citations - 12236
Matthew J. Grainge is an academic researcher from University of Nottingham. The author has contributed to research in topics: Population & Cohort study. The author has an hindex of 47, co-authored 147 publications receiving 10081 citations. Previous affiliations of Matthew J. Grainge include University of Leicester & Nottingham University Hospitals NHS Trust.
Papers
More filters
Familial Risk of Sjögren's Syndrome and Co-aggregation of Autoimmune Diseases in Affected Families: A Nationwide Population Study: Familial risks of Sjögren's syndrome
Chang-Fu Kuo,Matthew J. Grainge,Ana M. Valdes,Lai-Chu See,Shue-Fen Luo,Kuang-Hui Yu,Weiya Zhang,Michael Doherty +7 more
TL;DR: In this paper, the relative risks of other autoimmune diseases in relatives of patients with Sjögren's syndrome were investigated in the context of the study of Sjøgren's disease.
Journal ArticleDOI
The incidence of Kawasaki disease using hospital admissions data for England 2006-2021.
Myron O Odingo,Megan Rutter,Jonathan Bowley,Emily Peach,Peter Lanyon,Matthew J. Grainge,Peter Stillwell,Sean McPhail,Mary Bythell,Jeanette Aston,Sarah Stevens,Rachael McCormack,Paul A. Brogan,Fiona A Pearce +13 more
TL;DR: In this paper , the authors identified all cases in hospital episode statistics with an ICD-10 diagnostic code M303 (for Kawasaki Disease) between 1 April 2006 - 31 March 2021 and found >97% accuracy.
Journal ArticleDOI
Letter: different risks of venous thromboembolism in subsets of patients with inflammatory bowel diseases - authors' reply.
TL;DR: It is cautioned against considering anti‐TNF use as protective of venous thromboembolism beyond its ability to abolish disease activity without more direct evidence, and the proposed benefit of anti-TNF drugs as a mechanism explaining the results is less inclined to agree.
Journal ArticleDOI
Incidence and pattern of mycophenolate discontinuation associated with abnormal monitoring blood-test results: cohort study using data from the Clinical Practice Research Datalink Aurum
Georgina Nakafero,Matthew J. Grainge,Timothy R. Card,Christian D Mallen,Richard D Riley,Daniëlle A W M van der Windt,Christopher P. Fox,Maarten W. Taal,Guruprasad P. Aithal,Hywel C Williams,Abhishek Abhishek +10 more
TL;DR: MMF is uncommonly discontinued for blood-test abnormalities and even less often discontinued for severe blood- test abnormalities after the first year of prescription, especially in those without chronic kidney disease stage 3 or higher.